Budesonide MMX: Completed Phase III enrollment

Cosmo completed enrollment of 514 patients in a double-blind, European Phase III trial comparing 6 and 9 mg of oral Budesonide MMX vs. placebo. The study also includes an arm receiving 9 mg/day Entoc...